Dopaminergic Effects on Brown Adipose Tissue

• Status: Completed
• Trial end date: 2014-02-01
• Target enrollment: 0
• Participant gender: Male

Summary

In this study the investigators will investigate the effect of dopamine (bromocriptine) on Brown Adipose Tissue in lean, young, healthy males.

The investigators will also examine energy expenditure, body temperature and insulin sensitivity as measurements of Brown Adipose Tissue activity.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
• Treatments: Bromocriptine; Dopamine; Dopamine Agents; Dopamine Agonists

Criteria

Inclusion Criteria:

• Male

• Caucasian origin

• Subjects should be able and willing to give informed consent

• 18-30 years old

• BMI range of 19-25 kg/m2

Exclusion Criteria:

• Renal failure (creatinine>135mmol/l)

• Liver failure (AST/ (Alanine Aminotransferase) ALT > 3 times higher than the normal upper value)

• Daily use of prescription medication

• Known hypersensitivity to bromocriptine, domperidone maleate or other ergot alkaloids.

• Uncontrolled hypertension

• Known history of coronary artery disease, or other severe cardiovascular conditions (such as a prolonged Qtc-time), or symptoms / history of severe psychiatric disorders.

• Known cardiac valvulopathy

• Prolactin-releasing pituitary tumor (prolactinoma).

• Cases where stimulation of the gastric motility could be harmful: gastro-intestinal haemorrhage, mechanical obstruction or perforation.

• Subjects with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

• Prior participation in a research protocol involving radiation exposure in the last 2 years